Health plan strategy | Pharmacy spend | High-cost claims | ERISA fiduciary oversight
Medical Cost Strategies for Employers, Health Plans, Providers, and Healthcare Investors
Medical cost strategies based on UnitedHealthcare’s 2026 Health Trends Report describe a cost environment in which a small number of clinical, pharmacy, documentation, and site-of-care categories are driving a disproportionate share of medical trends. The practical question for plan sponsors, payors, providers, and investors is no longer whether costs are rising. It is where better data, better contracting, and better regulatory discipline can still change the outcome.
Pharmacy Claims, Catastrophic Claims over $100,000, Mental Health, Emergency Room Utilization, and ERISA Employer Funded Plan Fiduciary Oversight
According ot the United Healthcare report, these are the burning platforms right now in healthcare costs. I have added my own precursors to improved medical cost strategies after each bullet.
- Specialty pharmacy is now a classification and contracting risk. Traditional formulary and rebate strategies are not enough when a small share of utilization drives a majority of drug spend.
- Catastrophic claims require defensible evidence. High-cost oncology, cell, gene, and molecular therapies make clinical documentation, coding accuracy, coverage criteria, and stop-loss coordination central to financial control.
- Mental health, maternity, digestive disorders, and obesity care are converging. These categories should be governed as overlapping population-health risks, not as isolated benefit line items.
- Site-of-care strategy is a data observability problem. EMTALA requires that healthcare providers treat first, stabilize, and ask questions about insurance later. Avoidable emergency department use and declining virtual-care engagement require reliable claims, eligibility, EHR, and engagement data.
- Employer strategy is moving from blunt cost shifting to governed navigation. Copay-driven designs, Centers of Excellence, integrated benefits, and advocacy solutions work only when the underlying data, contracts, and fiduciary governance are sound.
UnitedHealthcare’s 2026 Health Trends Report, based on claims incurred from November 2024 through October 2025 across UnitedHealthcare’s self-funded and fully insured book of business, presents a consistent picture: healthcare costs are rising faster than inflation, the drivers are concentrated in a small number of high-cost categories, and the levers available to employers are narrower than they were even three years ago.
The headline figures are striking. According to the report, catastrophic claims of $100,000 or more grew 12.9% from 2024 to 2025. Pharmacy costs rose 11%, with similar projections for 2026. Specialty medications account for roughly 55% of total pharmacy benefit spend despite representing less than 2% of utilization. Mental health costs have risen 117% since 2019. Cell, gene, and molecular therapies – single-administration treatments costing between $370,000 and $4 million each – are coming to market faster than many plans can build coverage, stop-loss, and audit policies around them.
These are not abstract trend lines. They are operational problems for employers, health plans, hospital systems, benefit consultants, counsel, and healthcare investors. They are also precisely the types of problems No World Borders has worked on for nearly two decades: healthcare data, regulatory governance, reimbursement economics, medical coding, benefit design, claims audit, and healthcare transaction diligence.
The pharmacy cost problem is a classification, coverage, and contracting problem
UnitedHealthcare identifies three top employer pharmacy concerns: overall pharmacy costs, the affordability of higher-cost drugs, and the use and implications of GLP-1 therapies. The deeper issue is concentration risk. When less than 2% of utilization drives roughly 55% of total pharmacy benefit spend, traditional formulary tools and rebate-driven pharmacy benefit manager contracts cannot carry the full burden of cost management.
Drug costs behave this way in part because drugs are classified, covered, and reimbursed through systems that were not designed for a world in which a single therapy can cost the equivalent of a multi-year insurance premium. NDCs, HCPCS J-codes, formulary tiers, Pharmacy and Therapeutics Committee decisions, 340B eligibility, specialty-vs.-retail channel rules, prior authorization protocols, and medical-benefit drug billing all interact. No World Borders has written on these issues in Drug Pricing Expert and Classification Systems, Pharmacy Benefit Manager Expert Witness, and Pharmacy Benefit Managers Drug Pricing and Appeals.
Operationalize specialty pharmacy governance by mapping NDC, GPI, RxNorm, and HCPCS drug identifiers to claims, formulary, prior-authorization, rebate, MAC/WAC, and medical-benefit billing data. Use that evidence to audit PBM contract performance, test UCR and reimbursement assumptions, identify spread-pricing or rebate leakage, and preserve clinically necessary access to high-cost therapies.
For employers and plan fiduciaries, the action item is clear: specialty pharmacy governance should include classification review, medical-benefit and pharmacy-benefit alignment, rebate and spread-pricing transparency, biosimilar and site-of-care strategy, GLP-1 coverage criteria, and audit rights that are specific enough to be enforced. Public data standards and reference systems such as the FDA National Drug Code Directory and NLM RxNorm illustrate why terminology, identifier mapping, and reimbursement logic must be managed together.
Catastrophic claims and gene therapies require defensible audit evidence
A 12.9% year-over-year increase in catastrophic claims is more than a trend. It is a structural shift. Cell and gene therapies, expanded oncology indications, complex neonatal care, and earlier-onset chronic conditions are pushing claims that used to be rare into the routine planning horizon for mid-sized and large employers.
Centers of Excellence, prior authorization, case management, and stop-loss coverage can mitigate this risk, but only when the underlying clinical evidence is defensible. A high-cost claim should be evaluated against the medical record, plan language, medical necessity criteria, applicable coverage policies, ICD-10-CM/PCS and CPT coding, drug and device identifiers, and any stop-loss notification or reimbursement conditions. The FDA’s cellular and gene therapy resources show how quickly this category continues to develop. Medicare coverage resources such as CMS Local Coverage Determinations and the CMS Medicare Coverage Database also underscore the importance of linking clinical indications, documentation, coding, and coverage rules.
No World Borders has provided expert opinions on more than $2 billion in medical reimbursements and has led investor diligence on more than $8 billion in healthcare mergers and acquisitions. Across that work, the pattern is consistent: the difference between a defensible high-cost claim and a recoverable or contestable one is often documentation quality, coding accuracy, medical necessity support, and contract language. Our firm provides specialized opinions on Usual, Customary, and Reasonable (UCR) charges for medical bills in personal injury and medical malpractice cases, as well as expert analysis of reasonable reimbursement rates in disputes between healthcare providers and health plans. Our claims, reimbursement, and coding work is reflected in resources such as Medical Billing Expert Witness, ICD-10 Consulting, and Solutions Across the Continuum of Care.
Mental health, maternity, and comorbidity require integrated benefit governance
UnitedHealthcare reports that mental health costs have risen 117% since 2019, maternity costs rose 11.7% from 2024 to 2025, and digestive disorders rose 10.5%, partly as a downstream effect of GLP-1 utilization. These categories should not be analyzed in isolation. They are signals of a workforce in which complex and chronic conditions are presenting earlier, clustering with one another, and interacting with access, affordability, and site-of-care decisions.
How No World Borders can help: Treat mental health, maternity, digestive disorders, and obesity-related spending as connected population-health analytics signals, not isolated benefit categories. No World Borders can help employers, health plans, providers, and investors integrate claims, EHR, pharmacy, and X12 transaction data; evaluate DSM-5, ICD-10, and behavioral-health coding alignment; and use data quality, analytics, and AI-enabled observability to identify comorbidity clusters, access gaps, site-of-care leakage, and opportunities for targeted micro-interventions before conditions become high-cost claims. Consider observability-driven interventions in consumer-facing content.
My postgraduate work at Stanford Medical School in Biomedical Informatics and at Harvard Medical School in Clinical Bioethics, Risk Management, and Addiction Medicine has shaped how No World Borders approaches these categories. We have worked with behavioral health EHR vendors on DSM-5 and ICD-10 alignment, advised on prior authorization and coverage determinations, and consulted on the data and policy infrastructure needed to support population-health programs that move outcomes rather than simply move utilization.
ER overutilization and site-of-care decisions require data observability
UnitedHealthcare reports that emergency room visits rose 2.1% while virtual visits fell 16.1%, and that Gen Z relies on the ER more than any other generation while using primary care the least.
This is fundamentally a data observability and engagement problem. Employers and plans need to know whether claims, eligibility, provider directory, care navigation, virtual care, and EHR event data are complete, timely, mapped correctly, and actionable. Furthermore, it is incumbent on all trading partners across the healthcare ecosystem, including health plans such as UnitedHealthcare and healthcare providers, to ensure the accuracy and integrity of the data they exchange. Maintaining high standards for data quality is a shared responsibility that serves as the foundation for effective plan governance and improved member outcomes. AHRQ maintains emergency department research, data, and tools, while Telehealth.HHS.gov tracks telehealth trends, data, and research. Those resources reinforce the same point: the site-of-care strategy depends on usable information, not just member communications.
No World Borders applies data observability principles to claims, eligibility, EHR, and X12 transaction data, including 837, 835, 270, and 271 workflows. The five pillars of data observability – data quality monitoring, pipeline observability, infrastructure monitoring, user observability, and cost optimization – map directly onto the infrastructure plans and employers need to identify high-risk members, route them to appropriate care, and measure whether engagement programs are working. This work aligns with our broader Data Analytics for Healthcare, HIPAA Privacy, and HIPAA Privacy and Security capabilities.
Employer strategy is shifting from blunt cost-sharing to governed navigation
UnitedHealthcare’s data shows employers moving away from full-replacement HDHP/CDHP designs and toward copay-driven plan designs, Centers of Excellence, integrated benefits, and higher-level advocacy solutions. The shift is logical. When the most expensive categories are specialty drugs, catastrophic claims, complex comorbidities, and avoidable site-of-care decisions, a higher deductible alone does not solve the problem. It may simply move costs to members without improving clinical or financial outcomes.
The next generation of employer health plan strategy should combine benefit design with fiduciary oversight, vendor governance, data rights, claims audit rights, and measurable performance guarantees. The Department of Labor’s fiduciary responsibility resources and Form 5500 resources are important reminders that employee benefit plans are governance structures, not merely annual procurement exercises. No World Borders’ ERISA resources, including ERISA Expert Witness and Form 5500 under ERISA, address the same governance foundation.
For investors, the implication is equally important. A healthcare IT, payor, provider, specialty pharmacy, care navigation, or risk-bearing platform cannot be evaluated only on revenue growth. Diligence should examine claims integrity, coding risk, medical necessity workflows, PBM and specialty pharmacy exposure, privacy and security controls, risk adjustment methods, HEDIS and quality-measure infrastructure, and the degree to which reported savings are auditable. No World Borders has advised health plans, providers, healthcare IT companies, law firms, self-insured employers, and investors across these domains.
Where No World Borders fits
The UnitedHealthcare report is, in effect, a map of the cost-containment work that health plans, self-insured employers, hospital systems, healthcare vendors, and investors need to be doing in 2026 and 2027. At No World Borders, we have spent nearly two decades building the regulatory, data, and economic expertise needed to do that work across:
- ERISA plan administration, fiduciary oversight, service-provider governance, and Form 5500-related review;
- HIPAA Privacy and Security, HITECH safeguards, recognized cybersecurity practices, and healthcare data governance;
- Medicare Advantage risk adjustment, HEDIS quality measures, RADV and RAC audit defense, RAPS and encounter data analytics, and Medical Loss Ratio analytics;
- Specialty and prescription drug pricing, PBM contracting, formulary design, rebate and spread-pricing analysis, and 340B economics;
- Clinical documentation improvement, medical coding audits, medical necessity review, and revenue cycle analytics;
- Investor diligence on healthcare IT, payor, provider, revenue cycle, specialty pharmacy, and healthcare services transactions; and
- AI, data observability, claims analytics, EHR audits, and X12 transaction analysis.
If your organization is reading the 2026 Health Trends Report and recognizing that the strategies that worked in 2022 will not be sufficient for 2026 and 2027, the next step is to focus on the categories that drive the majority of spend: specialty pharmacy, catastrophic claims, comorbid behavioral and medical conditions, avoidable emergency department use, and vendor performance. These are the categories where better contracts, better data, and better documentation discipline can still bend the curve.